Schmidt Matthias, Voell Michael, Rahlff Ilka, Dietlein Markus, Kobe Carsten, Faust Michael, Schicha Harald
Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
Thyroid. 2008 Jul;18(7):755-60. doi: 10.1089/thy.2008.0008.
A number of studies show that the serum levels of antithyroid peroxidase antibodies (TPO-Ab) in patients with Hashimoto's thyroiditis decline during levothyroxine treatment, but do not provide quantitative data or report the fraction of patients in whom test for TPO-Ab became negative ("normalization percentage"). The objective of the present study was to provide this information.
This was a retrospective study of TPO-Ab concentrations in 36 women and 2 men (mean age 51 +/- 16 years; range 19-81 years) with Hashimoto's thyroiditis as defined by the following criteria: elevated plasma TPO-Ab and typical hypoechogenicity of the thyroid in high-resolution sonography at first presentation or during follow-up and low pertechnetate uptake in thyroid scintigraphy. When first studied 17 women and 1 man were not yet taking levothyroxine. The remaining 20 patients were receiving levothyroxine. At initial examination 18 patients had serum thyroid-stimulating hormone (TSH) concentrations above normal. Results of up to eight (mean = 5.8) measurements obtained over a mean period of 50 months while patients were receiving levothyroxine were analyzed. In addition, serum TSH, free triiodothyronine (fT3), and free thyroxine (fT4) were measured, and ultrasound of the neck was performed at each follow-up examination.
In terms of TPO-Ab levels, 35 of 38 patients (92%) had a decrease, 2 patients had undulating levels, and 1 patient had an inverse hyperbolic increase in her TPO-Ab levels. In the 35 patients in whom there were decreasing TPO-Ab values, the mean of the first value was 4779 IU/mL with an SD of 4099 IU/mL. The mean decrease after 3 months was 8%, and after 1 year it was 45%. Five years after the first value, TPO-Ab levels were 1456 +/- 1219 IU/mL, a decrease of 70%. TPO-Ab levels became negative, < 100 IU/mL, in only six patients, a normalization percentage of 16%. There were no correlations between changes in thyroid volume and changes in TPO-Ab.
Serum TPO-Ab levels decline in most patients with Hashimoto's thyroiditis who are taking levothyroxine, but after a mean of 50 months, TPO-Ab became negative in only a minority of patients.
多项研究表明,桥本甲状腺炎患者在左甲状腺素治疗期间抗甲状腺过氧化物酶抗体(TPO-Ab)的血清水平会下降,但未提供定量数据,也未报告TPO-Ab检测呈阴性的患者比例(“正常化百分比”)。本研究的目的是提供这一信息。
这是一项对36名女性和2名男性(平均年龄51±16岁;范围19 - 81岁)桥本甲状腺炎患者TPO-Ab浓度的回顾性研究,其定义依据以下标准:首次就诊或随访期间血浆TPO-Ab升高、高分辨率超声检查显示甲状腺典型低回声,以及甲状腺闪烁显像中高锝酸盐摄取降低。首次研究时,17名女性和1名男性尚未服用左甲状腺素。其余20名患者正在接受左甲状腺素治疗。初次检查时,18名患者血清促甲状腺激素(TSH)浓度高于正常。分析了患者接受左甲状腺素治疗期间平均50个月内最多8次(平均 = 5.8次)测量的结果。此外,每次随访时均测量血清TSH、游离三碘甲状腺原氨酸(fT3)和游离甲状腺素(fT4),并进行颈部超声检查。
就TPO-Ab水平而言,38名患者中有35名(92%)下降,2名患者水平波动,1名患者TPO-Ab水平呈反双曲线升高。在TPO-Ab值下降的35名患者中,首个值的平均值为4779 IU/mL,标准差为4099 IU/mL。3个月后的平均降幅为8%,1年后为45%。首个值出现5年后,TPO-Ab水平为1456±1219 IU/mL,降幅为70%。只有6名患者TPO-Ab水平变为阴性,即<100 IU/mL,正常化百分比为16%。甲状腺体积变化与TPO-Ab变化之间无相关性。
大多数接受左甲状腺素治疗的桥本甲状腺炎患者血清TPO-Ab水平会下降,但平均50个月后,只有少数患者TPO-Ab变为阴性。